Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1992 May;76(5):259–261. doi: 10.1136/bjo.76.5.259

Does aspirin affect the rate of cataract formation? Cross-sectional results during a randomised double-blind placebo controlled trial to prevent serious vascular events. UK-TIA Study Group.

PMCID: PMC504250  PMID: 1390504

Abstract

A total of 2435 patients with transient ischaemic attack or minor ischaemic stroke were entered into the UK-TIA aspirin trial and randomised to treatment with aspirin 1200 mg/day, aspirin 300 mg/day, or placebo. At a single point in time during the trial patients were examined ophthalmoscopically for evidence of cataracts. The length of time that each patient had been participating in the trial at the time of ophthalmic examination varied from 1 to 5 years. The prevalence of cataracts was similar in patients allocated aspirin and patients allocated placebo irrespective of the length of time that they had been in the trial. These findings suggest that aspirin taken in a dose of 300 to 1200 mg daily for a few years does not prevent cataracts.

Full text

PDF
259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cotlier E. Senile cataracts: evidence for acceleration by diabetes and deceleration by salicylate. Can J Ophthalmol. 1981 Jul;16(3):113–118. [PubMed] [Google Scholar]
  2. Cotlier E., Sharma Y. R. Aspirin and senile cataracts in rheumatoid arthritis. Lancet. 1981 Feb 7;1(8215):338–339. doi: 10.1016/s0140-6736(81)91965-6. [DOI] [PubMed] [Google Scholar]
  3. Cotlier E., Sharma Y. R., Niven T., Brescia M. Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. Am J Med. 1983 Jun 14;74(6A):83–90. doi: 10.1016/0002-9343(83)90534-x. [DOI] [PubMed] [Google Scholar]
  4. Crompton M., Rixon K. C., Harding J. J. Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract. Exp Eye Res. 1985 Feb;40(2):297–311. doi: 10.1016/0014-4835(85)90014-4. [DOI] [PubMed] [Google Scholar]
  5. Harding J. J., van Heyningen R. Drugs, including alcohol, that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide. Br J Ophthalmol. 1988 Nov;72(11):809–814. doi: 10.1136/bjo.72.11.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kewitz H., Nitz M., Gaus V. Aspirin and cataract. Lancet. 1986 Sep 20;2(8508):689–689. doi: 10.1016/s0140-6736(86)90197-2. [DOI] [PubMed] [Google Scholar]
  7. Kini M. M., Leibowitz H. M., Colton T., Nickerson R. J., Ganley J., Dawber T. R. Prevalence of senile cataract, diabetic retinopathy, senile macular degeneration, and open-angle glaucoma in the Framingham eye study. Am J Ophthalmol. 1978 Jan;85(1):28–34. doi: 10.1016/s0002-9394(14)76661-9. [DOI] [PubMed] [Google Scholar]
  8. Paganini-Hill A., Chao A., Ross R. K., Henderson B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989 Nov 18;299(6710):1247–1250. doi: 10.1136/bmj.299.6710.1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., Warlow C., Hafner B., Thompson E., Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):313–316. doi: 10.1136/bmj.296.6618.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rao G. N., Lardis M. P., Cotlier E. Acetylation of lens crystallins: a possible mechanism by which aspirin could prevent cataract formation. Biochem Biophys Res Commun. 1985 May 16;128(3):1125–1132. doi: 10.1016/0006-291x(85)91057-5. [DOI] [PubMed] [Google Scholar]
  11. Siegel D., Sperduto R. D., Ferris F. L., 3rd Is ASA therapy for cataracts justified? Can J Ophthalmol. 1982 Jun;17(3):135–137. [PubMed] [Google Scholar]
  12. Swamy M. S., Abraham E. C. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. Invest Ophthalmol Vis Sci. 1989 Jun;30(6):1120–1126. [PubMed] [Google Scholar]
  13. West S. K., Muñoz B. E., Newland H. S., Emmett E. A., Taylor H. R. Lack of evidence for aspirin use and prevention of cataracts. Arch Ophthalmol. 1987 Sep;105(9):1229–1231. doi: 10.1001/archopht.1987.01060090087034. [DOI] [PubMed] [Google Scholar]
  14. van Heyningen R., Harding J. J. Do aspirin-like analgesics protect against cataract? A case-control study. Lancet. 1986 May 17;1(8490):1111–1113. doi: 10.1016/s0140-6736(86)91834-9. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES